You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

cMet exon 14 skipping

Showing 1 - 25 of 6,386
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain

Completed
  • Metastatic Non-Small Cell Lung Cancer
  • East Hanover, New Jersey
    18 Novartis Investigative Sites in the US
Dec 29, 2022

Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

Recruiting
  • Non-Small Cell Lung Carcinoma
  • Capmatinib 150 mg
  • Capmatinib 200 mg
  • Guwahati, Assam, India
  • +7 more
Dec 19, 2022

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer Trial in San Francisco (Capmatinib, Trametinib)

    Recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • Stage IV Lung Cancer
    • San Francisco, California
      University of California San Francisco
    Aug 15, 2022

    Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

    Not yet recruiting
    • Recurrent Lung Non-Small Cell Carcinoma
    • Stage IV Lung Cancer AJCC v8
    • Biospecimen Collection
    • +5 more
    • (no location specified)
    Sep 7, 2023

    Advanced NSCLC Trial (CT053PTSA)

    Not yet recruiting
    • Advanced NSCLC
    • (no location specified)
    Jul 29, 2021

    NSCLC (NSCLC) Trial in China (Capmatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Xiamen, Fujian, China
    • +18 more
    Jan 27, 2023

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    Carcinoma, Non-Small Cell Lung, NSCLC, Non-Small-Cell Lung Carcinoma Trial (Capmatinib)

    Available
    • Carcinoma, Non-Small Cell Lung
    • +3 more
    • (no location specified)
    Aug 31, 2021

    NSCLC Trial in United States (capmatinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • La Jolla, California
    • +7 more
    Oct 5, 2022

    Malignant Non-small Cell Tumor of Lung Stage IV Trial in Boston (Capmatinib (INC280))

    Completed
    Has Results
    • Malignant Non-small Cell Neoplasm of Lung Stage IV
    • Capmatinib (INC280)
    • Boston, Massachusetts
      Massachusetts General Hospital
    Mar 11, 2022

    NSCLC Trial in Worldwide (INC280 (capmatinib))

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • INC280 (capmatinib)
    • Long Beach, California
    • +95 more
    Dec 29, 2022

    NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

    Not yet recruiting
    • NSCLC
    • +5 more
    • (no location specified)
    Dec 7, 2022

    Solid Tumor, MET Exon 14 Skipping Mutation, MET Amplification Trial in Korea, Republic of (Tepotinib)

    Recruiting
    • Solid Tumor
    • +2 more
    • Hwasun, Chonnam, Korea, Republic of
    • +21 more
    Nov 30, 2020

    Duchenne Muscular Dystrophy Trial in Worldwide (SRP-4045, SRP-4053, Placebo)

    Active, not recruiting
    • Duchenne Muscular Dystrophy
    • Phoenix, Arizona
    • +74 more
    Jan 17, 2023

    Cancer, Lung Cancer Metastatic, MET Gene Mutation Trial in Seoul (Capmatinib)

    Unknown status
    • Cancer
    • +2 more
    • Seoul, Korea, Republic of
      Asan Medical Center
    Oct 1, 2018

    NSCLC Trial in Worldwide (Capmatinib, Amivantamab)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Orange, California
    • +40 more
    Aug 3, 2022

    NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • MK-2870
    • +2 more
    • (no location specified)
    Oct 3, 2023

    Advanced (Stage IIIB/IV) NSCLC (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification Trial in Worldwide

    Active, not recruiting
    • Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
    • Duarte, California
    • +140 more
    Jun 7, 2022

    NSCLC Metastatic, NSCLC Stage III Trial in Worldwide (Avelumab, Axitinib, Palbociclib)

    Active, not recruiting
    • Non-small Cell Lung Cancer Metastatic
    • Non-small Cell Lung Cancer Stage III
    • La Jolla, California
    • +5 more
    Aug 12, 2022

    Duchenne Muscular Dystrophy Trial in Portland (NS-089/NCNP-02)

    Not yet recruiting
    • Duchenne Muscular Dystrophy
    • Portland, Oregon
      Shriners Hospital for Children
    Aug 16, 2023

    Special Drug Use-results Surveillance of Tabrecta Tablets

    Recruiting
    • Non-small Cell Lung Cancer
    • Tabrecta tablets
    • Nagoya, Aichi, Japan
    • +44 more
    Aug 1, 2022

    Duchenne Muscular Dystrophy Trial (NS-050/NCNP-03, Placebo)

    Not yet recruiting
    • Duchenne Muscular Dystrophy
    • (no location specified)
    Sep 19, 2023

    NSCLC Trial in Guangzhou (PLB1001)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Aug 15, 2023

    Solid Tumor Trial in El Segundo (AMG 337)

    Withdrawn
    • Solid Tumor
    • AMG 337
    • El Segundo, California
      Chan Soon-Shiong Institute for Medicine
    Aug 23, 2019